Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347253 · ClinicalTrials.gov registry record
STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT
A clinical trial, sponsored by Amicus Therapeutics.
- Terminated
- Registry status
- 12
- Enrollment target
NCT03347253 is a clinical trial that was terminated before completion, run by Amicus Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT03347253 was terminated before completion, sponsored by Amicus Therapeutics.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate changes in key clinical outcome measures (eg, motor, respiratory, fatigue) in adult subjects with late-onset Pompe disease (LOPD) subjects receiving standard-of-care enzyme replacement therapy (ERT). Additionally, information gained may be used in the design and conduct of future studies in LOPD subjects.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2018-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03347253
The ClinicalTrials.gov registry entry for NCT03347253 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03347253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03347253 about?
NCT03347253 is a clinical study titled "STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT". The purpose of the study is to evaluate changes in key clinical outcome measures (eg, motor, respiratory, fatigue) in adult subjects with late-onset Pompe disease (LOPD) subjects receiving standard-of-care enzyme replacement therapy (ERT). Additionally, information gained may be used in the design a...
What is the current status of trial NCT03347253?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2017-12-08. Estimated completion is 2018-11-30.
Who is sponsoring clinical trial NCT03347253?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.